286 related articles for article (PubMed ID: 32276399)
1. Interferon Response in Hepatitis C Virus-Infected Hepatocytes: Issues to Consider in the Era of Direct-Acting Antivirals.
Sung PS; Shin EC
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32276399
[TBL] [Abstract][Full Text] [Related]
2. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons.
Thomas E; Gonzalez VD; Li Q; Modi AA; Chen W; Noureddin M; Rotman Y; Liang TJ
Gastroenterology; 2012 Apr; 142(4):978-88. PubMed ID: 22248663
[TBL] [Abstract][Full Text] [Related]
3. Innate and adaptive immune responses in HCV infections.
Heim MH; Thimme R
J Hepatol; 2014 Nov; 61(1 Suppl):S14-25. PubMed ID: 25443342
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of antiviral effect of type I, II, and III interferons on direct-acting antiviral-resistant hepatitis C virus.
Hamana A; Takahashi Y; Uchida T; Nishikawa M; Imamura M; Chayama K; Takakura Y
Antiviral Res; 2017 Oct; 146():130-138. PubMed ID: 28864074
[TBL] [Abstract][Full Text] [Related]
5. HBV Bypasses the Innate Immune Response and Does Not Protect HCV From Antiviral Activity of Interferon.
Mutz P; Metz P; Lempp FA; Bender S; Qu B; Schöneweis K; Seitz S; Tu T; Restuccia A; Frankish J; Dächert C; Schusser B; Koschny R; Polychronidis G; Schemmer P; Hoffmann K; Baumert TF; Binder M; Urban S; Bartenschlager R
Gastroenterology; 2018 May; 154(6):1791-1804.e22. PubMed ID: 29410097
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C virus replication in mouse cells is restricted by IFN-dependent and -independent mechanisms.
Nandakumar R; Finsterbusch K; Lipps C; Neumann B; Grashoff M; Nair S; Hochnadel I; Lienenklaus S; Wappler I; Steinmann E; Hauser H; Pietschmann T; Kröger A
Gastroenterology; 2013 Dec; 145(6):1414-23.e1. PubMed ID: 23973921
[TBL] [Abstract][Full Text] [Related]
7. Baseline Intrahepatic and Peripheral Innate Immunity are Associated with Hepatitis C Virus Clearance During Direct-Acting Antiviral Therapy.
Alao H; Cam M; Keembiyehetty C; Zhang F; Serti E; Suarez D; Park H; Fourie NH; Wright EC; Henderson WA; Li Q; Liang TJ; Rehermann B; Ghany MG
Hepatology; 2018 Dec; 68(6):2078-2088. PubMed ID: 29704252
[TBL] [Abstract][Full Text] [Related]
8. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
[TBL] [Abstract][Full Text] [Related]
9. Role of Interferons in Chronic Hepatitis C Infection.
Scagnolari C; Monteleone K; Cacciotti G; Antonelli G
Curr Drug Targets; 2017; 18(7):844-850. PubMed ID: 26844564
[TBL] [Abstract][Full Text] [Related]
10. The Role of Type III Interferons in Hepatitis C Virus Infection and Therapy.
Bruening J; Weigel B; Gerold G
J Immunol Res; 2017; 2017():7232361. PubMed ID: 28255563
[TBL] [Abstract][Full Text] [Related]
11. DDX60L Is an Interferon-Stimulated Gene Product Restricting Hepatitis C Virus Replication in Cell Culture.
Grünvogel O; Esser-Nobis K; Reustle A; Schult P; Müller B; Metz P; Trippler M; Windisch MP; Frese M; Binder M; Fackler O; Bartenschlager R; Ruggieri A; Lohmann V
J Virol; 2015 Oct; 89(20):10548-68. PubMed ID: 26269178
[TBL] [Abstract][Full Text] [Related]
12. Hepatic expression levels of interferons and interferon-stimulated genes in patients with chronic hepatitis C: A phenotype-genotype correlation study.
Noureddin M; Rotman Y; Zhang F; Park H; Rehermann B; Thomas E; Liang TJ
Genes Immun; 2015; 16(5):321-9. PubMed ID: 26020282
[TBL] [Abstract][Full Text] [Related]
13. Multi-step regulation of interferon induction by hepatitis C virus.
Oshiumi H; Funami K; Aly HH; Matsumoto M; Seya T
Arch Immunol Ther Exp (Warsz); 2013 Apr; 61(2):127-38. PubMed ID: 23292079
[TBL] [Abstract][Full Text] [Related]
14. (-)-Epigallocatechin-3-gallate enhances poly I:C-induced interferon-λ1 production and inhibits hepatitis C virus replication in hepatocytes.
Wang YZ; Li JL; Wang X; Zhang T; Ho WZ
World J Gastroenterol; 2017 Aug; 23(32):5895-5903. PubMed ID: 28932081
[TBL] [Abstract][Full Text] [Related]
15. IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection.
Park H; Serti E; Eke O; Muchmore B; Prokunina-Olsson L; Capone S; Folgori A; Rehermann B
Hepatology; 2012 Dec; 56(6):2060-70. PubMed ID: 22706965
[TBL] [Abstract][Full Text] [Related]
16. Genetic Polymorphisms within Interferon-λ Region and Interferon-λ3 in the Human Pathophysiology: Their Contribution to Outcome, Treatment, and Prevention of Infections with Hepatotropic Viruses.
Grzegorzewska AE
Curr Med Chem; 2019; 26(25):4832-4851. PubMed ID: 30027841
[TBL] [Abstract][Full Text] [Related]
17. Innate immunity and HCV.
Heim MH
J Hepatol; 2013 Mar; 58(3):564-74. PubMed ID: 23063572
[TBL] [Abstract][Full Text] [Related]
18. Understanding the molecular mechanism(s) of hepatitis C virus (HCV) induced interferon resistance.
Qashqari H; Al-Mars A; Chaudhary A; Abuzenadah A; Damanhouri G; Alqahtani M; Mahmoud M; El Sayed Zaki M; Fatima K; Qadri I
Infect Genet Evol; 2013 Oct; 19():113-9. PubMed ID: 23831932
[TBL] [Abstract][Full Text] [Related]
19. Antiviral and Immunoregulatory Effects of Indoleamine-2,3-Dioxygenase in Hepatitis C Virus Infection.
Lepiller Q; Soulier E; Li Q; Lambotin M; Barths J; Fuchs D; Stoll-Keller F; Liang TJ; Barth H
J Innate Immun; 2015; 7(5):530-44. PubMed ID: 25792183
[TBL] [Abstract][Full Text] [Related]
20. Rapid hepatitis C virus clearance by antivirals correlates with immune status of infected patients.
Sasaki R; Meyer K; Moriyama M; Kato N; Yokosuka O; Ray RB; Aurora R; Ray R; Kanda T
J Med Virol; 2019 Mar; 91(3):411-418. PubMed ID: 30192392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
